Whitehawk Therapeutics Inc
NASDAQ:WHWK · NASDAQ Global Market
+$0.10 today
Vol 0.35M · Avg 0.30M
Income Statement
Follow revenue through to earnings
Review sales, margins, expenses, and profit trends to see what is actually driving reported earnings over time.
Stock Ticker Earnings Waterfall
NASDAQ:WHWK · Revenue to Net Income
Key Ratios
Analysis
$0 of revenue converted into -$115.8M of net income for the selected period. Gross margin is 0.0% and net margin is 0.0%, showing how much revenue survives after costs and taxes. EPS is $-1.68, tying the income statement back to per-share earnings.
Income Statement
Annual data · 5 periods
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $7.1M -72.5% | $26.0M +6.7% | $24.4M +60.1% | $15.2M +1258.6% | $1.1M | $809.6M | $921.6M | $731.2M |
| Cost of Revenue | $760.0K -98.6% | $54.1M +4.5% | $51.7M +52.2% | $34.0M +72.8% | $19.7M | $725.6M | $804.0M | $882.4M |
| Gross Profit | $6.4M +122.7% | -$28.1M -2.5% | -$27.4M -45.8% | -$18.8M -1.2% | -$18.6M | $8.9B | $7.6B | $6.2B |
| Gross Margin | 89.4% +197.4pp | -108.0% +4.4pp | -112.4% +11.0pp | -123.4% +1532.8pp | -1656.3% | 9.8% | 28.9% | 38.3% |
| Research & Development | $91.0M +78.3% | $51.0M +4.3% | $48.9M +49.8% | $32.7M +66.0% | $19.7M | $983.2M | $1.3B | $490.4M |
| Selling, General & Admin | $29.8M -18.8% | $36.7M -17.5% | $44.5M +10.9% | $40.2M +117.0% | $18.5M | $620.6M | $923.0M | -$1.5B |
| Operating Expenses | $120.8M +206.7% | $39.4M -11.6% | $44.5M +1.5% | $43.9M -52.6% | $92.7M | $5.3B | $7.0B | $8.7B |
| Depreciation & Amortization | $79.0K -59.1% | $193.0K +14.2% | $169.0K +6.3% | $159.0K +51.4% | $105.0K | $374.2M | $1.2B | $631.8M |
| EBITDA | -$20.5M +68.3% | -$64.6M +1.1% | -$65.4M -11.2% | -$58.8M -59.1% | -$37.0M | -$15.2B | $6.8B | $9.3B |
| EBITDA Margin | -287.2% -38.4pp | -248.7% +19.7pp | -268.4% +118.0pp | -386.4% +2913.2pp | -3299.6% | 5.6% | 46.3% | 42.0% |
| Operating Income | -$114.4M -69.6% | -$67.5M +6.2% | -$71.9M -14.8% | -$62.7M +43.6% | -$111.2M | $12.3B | $14.0B | -$15.7B |
| Operating Margin | -1601.1% -1341.5pp | -259.6% +35.7pp | -295.4% +116.6pp | -411.9% +9518.1pp | -9930.1% | 16.6% | 24.1% | 22.0% |
| Interest Income | $6.2M +58.8% | $3.9M -38.7% | $6.4M +166.9% | $2.4M +18346.2% | $13.0K | -$1.5B | -$1.6B | $405.0M |
| Interest Expense | $0 -100.0% | $154.0K -33.3% | $231.0K +0.4% | $230.0K -65.4% | $665.0K | $1.1B | $1.0B | $1.2B |
| Other Income / Expenses | $93.8M +2390.2% | $3.8M -38.9% | $6.2M +184.5% | $2.2M +92.0% | $1.1M | -$1.5B | $1.4B | $1.2B |
| Income Before Tax | -$20.6M +67.7% | -$63.7M +3.2% | -$65.8M -8.7% | -$60.5M +45.0% | -$110.1M | $3.3B | $4.9B | $3.6B |
| Pre-Tax Margin | -288.3% -43.1pp | -245.1% +24.9pp | -270.0% +127.7pp | -397.7% +9431.6pp | -9829.3% | 20.8% | 18.7% | 26.2% |
| Income Tax Expense | $0 | $0 | $0 | $0 -100.0% | $2.0K | $1.3B | -$1.6B | $745.2M |
| Net Income | -$20.6M +67.7% | -$63.7M +3.2% | -$65.8M -8.7% | -$60.5M +45.0% | -$110.1M | $4.9B | $4.8B | $4.7B |
| Net Margin | -288.3% -43.1pp | -245.1% +24.9pp | -270.0% +127.7pp | -397.7% +9431.8pp | -9829.5% | 12.4% | 17.5% | 22.5% |
| EPS (Basic) | -$0 +86.0% | -$2 +3.3% | -$2 +9.3% | -$3 +78.3% | -$12 | $400.8M | $703.2M | $1.3B |
| EPS (Diluted) | -$0 +86.0% | -$2 +3.3% | -$2 +9.3% | -$3 +78.3% | -$12 | $766.2M | $609.4M | $452.6M |
| Weighted Avg Shares | $61.9M +129.0% | $27.0M +0.4% | $26.9M +19.6% | $22.5M +153.8% | $8.9M | $757.8M | $925.8M | $1.1B |
| Weighted Avg Shares (Diluted) | $61.9M +129.0% | $27.0M +0.4% | $26.9M +19.6% | $22.5M +152.3% | $8.9M | $1.2B | $924.4M | $678.0M |
Older periods hidden.
Sign in to unlockCompetitors
Peer companies in the same sector
Immix Biopharma, Inc.
NASDAQ:IMMX
$459.70M
Ovid Therapeutics Inc.
NASDAQ:OVID
$303.33M
Zentalis Pharmaceuticals, Inc.
NASDAQ:ZNTL
$266.95M
MacroGenics, Inc.
NASDAQ:MGNX
$251.71M
Context Therapeutics Inc.
NASDAQ:CNTX
$127.71M
Oncolytics Biotech Inc.
NASDAQ:ONCY
$80.59M
Pliant Therapeutics, Inc.
NASDAQ:PLRX
$69.97M
Clene Inc.
NASDAQ:CLNN
$60.20M
Tevogen Bio Holdings Inc.
TVGN
$43.84M
Atossa Therapeutics, Inc.
ATOS
$21.18M
SEC Filings
Recent regulatory filings
No filings found.
How much revenue does WHWK generate?
Whitehawk Therapeutics Inc (WHWK) reported $7.14M of revenue in fiscal 2025.
Is WHWK profitable?
Whitehawk Therapeutics Inc (WHWK) reported -$20,596,000.00 of net income, with a net margin of -288.3%.
Explore More
Continue the stock analysis
Jump to another research area for this company.